摘要 |
Disclosed herein are compounds of the formula: A-N(R1)C(O)CH2CHR2C(O)-B, wherein A is an oxygen-bearing radical selected from the group consisting of: (a) HO-CH(R3)CH2 wherein R3 is, for example, hydrogen, lower alkyl, lower cycloalkyl, phenyl or an unsubstituted five- or six-membered heterocyclic ring containing one or two hereroatoms selected from the group of N, O or S; (b) HO-CH2CH(R4) wherein R4 is, for example, lower alkyl or phenyl(lower)alkyl; and (c) HO-CR5(R6)CH2 wherein each of R5 and R6 is lower alkyl; or R5 and R6 together with the carbon atom to which they are attached form a 1,1-(lower cycloalkanediyl), 1,1-(4-hydroxycyclohexanediyl) or 1,1-(4-oxocyclohexanediyl); (d) (lower alkoxy)CR5A(R6A)CH2 wherein each of R5A and R6A is lower alkyl; or R5A and R6A together with the carbon atom to which they are attached form a 1,1-(lower cycloalkanediyl); and (e) (lower alkyl)C(O)CH2; R1 is, for example, benzyl, alkyl, a substituted alkyl such as cyclohexylmethyl, or R7R8NC(O)CH2 wherein R7 and R8 are alkyl such as methyl or ethyl; R2 is, for example, alkyl, cycloalkylmethyl, 1(H)-imidazol-4-ylmethyl, 4-thiazolylmethyl or (2-amino-4-thiazolyl)methyl; and B is a renin substrate transition state mimic, for example, (1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl)amino. The compounds inhibit renin activity and are indicated for the treatment of hypertension and congestive heart failure. |
申请人 |
BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. |
发明人 |
ANDERSON, PAUL, CATES;HALMOS, TEDDY;JUNG, GRACE, LORENA;POUPART, MARC-ANDRE;SIMONEAU, BRUNO |